The House That CMS Built Is Being Rebuilt
Organogenesis went from a $226M quarter to a 58% revenue collapse in six months; now it's restructuring twice, selling stock, and betting a year-out Amnuvx approval on its future.
ORGO · Earnings Call · 2026-08-06
When the Reimbursement Rug Came Out
There is almost nothing in the skin substitute market that looks like it did a year ago, and Organogenesis has gone from the chief beneficiary of that change to its most exposed hostage. The story arc in two quarters: management guided Q4 2025 to a midpoint they then “beat our midpoint of our guidance by about $50 million” — Gary Gillheeney, Chief Executive Officer · 2026-02-26 — the company closed the year on a $226M quarter, its best ever. Then CMS's late-December actions on coverage, payment, and its comments about product wastage hit the market like a brick. By Q1 2026, revenue had collapsed to $37M; Q2 came in at $42.8M of net product revenue, down 58% year-over-year, with Advanced Wound Care down 61%. Management's framing of the quarter opens with the cause: “the significant contraction and slow pace of recovery in the skin substitute market as a result of the actions and comments from CMS in late December of 2025” — Gary Gillheeney, Chief Executive Officer · 2026-08-06. The fundamentals confirm the magnitude. Total Revenue went vertical — from a $226M peak in Q4 2025 to $37M in Q1 2026, a single-quarter collapse of roughly 84%. The margin engine took a comparable hit: Gross margin fell from 73% a year ago to 45% GAAP (49% non-GAAP) in Q2, with the fundamentals descriptor showing the series collapsing into reporting gaps through 2025-26.Guidance, Twice-Cut, and a Second Restructuring
The prior call already laid out the mechanics of the disruption — the WISeR prior-authorization failures, a large MAC struggling to process claims, and, in Gary Gillheeney's words, “the level of complexity of that change was more than we've seen in the past” — Gary Gillheeney, Chief Executive Officer · 2026-05-08. Back then, management still expected the back half to recover. That thesis is now explicitly abandoned, at least in pace. Full-year 2026 total revenue guidance was cut a second time, from a 45-52% decline to a 62-68% decline — $179M to $215M — with Dave Francisco describing a "more measured" path, sequential growth weighted to Q4, and “positive adjusted EBITDA generation in the fourth quarter” — David Francisco, Chief Financial Officer · 2026-08-06 as the target. Supporting that is a second workforce restructuring — 138 employees, roughly $18M of annualized savings, on top of the March restructuring's $13.4M, for a combined $32M+ of annual expense reduction. The Wound Care expense base is being re-architected around a market management believes will heal slowly while they gain share into the trough.The share-gain claim is the heart of the bull case, and Q2 lends it support: Advanced Wound Care unit volume grew 30% sequentially, and Gary frames it as a flight to quality — “products without RCTs are at significant risk ... There's a flight to quality, which is why we're seeing the 30% growth” — Gary Gillheeney, Chief Executive Officer · 2026-08-06. The problem is the shrinking base: competitors may be exiting or diversifying away from wound care, but the denominator is collapsing too.So what we've seen is a contraction of the market by about 63%. That's an enormous contraction in the market. We're certainly down less than that. We believe we've taken share.
Amnuvx, Cash, and the Option on the Future
What's genuinely new this quarter is concrete progress on Amnuvx, the renamed ReNu knee-osteoarthritis biologic. The FDA accepted the BLA and set a PDUFA date of April 24, 2027. Gary is explicit that, if approved, it would be the first biologic in a space serving more than 30 million Americans with symptomatic knee OA, launching with a temporary code and ramping into late 2027/early 2028: “the product is unique. There is no other biologic in this space, and we're pretty excited about it” — Gary Gillheeney, Chief Executive Officer · 2026-08-06. Meanwhile, Dermagraft's relaunch slips roughly a year to mid-2028 as the company slows that manufacturing build-out to preserve cash. Cash is the constraint that ties it all together. The balance sheet showed $46.8M at June 30 (versus $94.3M at year-end) and no debt — a burn of nearly $50M in six months. After quarter end, management struck an ATM agreement for up to $75M. R&D rose 76% year-over-year, but $5.6M of that was one-time termination costs as the company pruned programs, and a $30M non-cash valuation allowance on deferred tax assets is a vivid, if mechanical, admission that the near-term earnings picture is impaired. Nothing about the close-out remarks suggests retreat:Whether that trust converts to revenue at the guided pace — or whether the market's trough is deeper than even the second cut assumes — is the open question. The stock is down roughly 81% from its 2019 peak and about 24% over the last three months, and the market is already voting on the pessimistic end of the range for a company now worth just over $300 million. The real swing factor is Amnuvx, a year away; Organogenesis's current value is increasingly an option on that approval, layered on a share-gain story in a market whose floor nobody has yet seen.Organogenesis is doubling down on wound care. ... Customer trust matters now in this new market more than ever before, and simply put, we believe we have the best evidence-based skin substitute products in wound care, bar none.